Changes in utilization and discard of HCV-antibody positive deceased-donor kidneys in the era of direct-acting antiviral therapy

BACKGROUND: The availability of direct-acting antiviral (DAA) therapy might have impacted use of HCV-infected (HCV+) deceased-donor kidneys for transplantation. METHODS: We used 2005-2018 SRTR data to identify 18 936 candidates willing to accept HCV+ kidneys and 3348 HCV+ recipients of HCV+ kidneys....

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Transplantation
Main Authors: Bowring, Mary G., Kucirka, Lauren M., Massie, Allan B., Ishaque, Tanveen, Bae, Sunjae, Shaffer, Ashton A., Wang, Jacqueline Garonzik, Sulkowski, Mark, Desai, Niraj, Segev, Dorry L., Durand, Christine M.
Formato: Artigo
Idioma:Inglês
Publicado em: 2018
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6249103/
https://ncbi.nlm.nih.gov/pubmed/29912046
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/TP.0000000000002323
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados